# A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct03933735/  
OnCo record `nct03933735` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TNB-383B in multiple myeloma, run by AbbVie, active and no longer recruiting.

## Summary

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT03933735 by AbbVie, with 220 participants enrolled, started 2019-06-24 and due to reach its primary completion in 2026-05. Interventions recorded: TNB-383B.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03933735
- Phase: 1/2
- Setting: A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
- Sponsor: AbbVie
- Enrolled: 220

## Sources

- ClinicalTrials.gov NCT03933735: https://clinicaltrials.gov/study/NCT03933735

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct03933735.json